APPROACH UNDER REVIEW: `prompt-only`

SCENARIO ID: scenario_09
APP DESCRIPTION: DermaScan is a smartphone app that takes a photo of a skin lesion and uses a CNN to classify it as benign, suspicious, or urgent. We market it as a triage aid for primary-care physicians; the GP takes the photo on their phone with informed patient consent. EU + CH. Trained on the ISIC archive.

DEVELOPER PERSONA: Dermatology AI startup CTO, technically strong, has consulted with regulatory but eager to launch.

EXPECTED HERA DIMENSIONS (gold standard): P1.D1, P1.D2, P1.D5, P2.D1, P2.D5, P3.D5, P5.D1, P5.D2, P5.D3, P6.D1, P6.D3, P6.D5, P7.D1, P7.D2, P7.D3, P7.D5

TRANSCRIPT:
### USER
DermaScan is a smartphone app that takes a photo of a skin lesion and uses a CNN to classify it as benign, suspicious, or urgent. We market it as a triage aid for primary-care physicians; the GP takes the photo on their phone with informed patient consent. EU + CH. Trained on the ISIC archive.

### ASSISTANT
What data governance framework do you use to ensure that the patient photos and associated metadata are stored, processed, and shared in compliance with GDPR and the EU AI Act?

### USER
Photos are stored pseudonymized for 5 years for retraining, retention is a separate opt-in consent the patient can decline or later withdraw, but I'll admit we haven't fully built out or documented the GDPR erasure-on-request workflow, including pulling images already in a retraining set.

### ASSISTANT
What specific steps are you taking to ensure that the pseudonymization of patient photos meets the GDPR requirement for "anonymization" where possible, and how do you plan to address the risk of re-identification in the retraining set? [P2.D3]

### USER
Photos stored 5 years for retraining; pseudonymized.

### ASSISTANT
What specific measures are you implementing to ensure that the pseudonymization of patient data meets the GDPR standard of "adequate security" and prevents re-identification, especially when the data is used for retraining the CNN model? [P2.D3]

### USER
We haven't formally defined contraindications or exclusion criteria yet. The app will classify any lesion photo a GP feeds it — we don't currently screen out or refuse the harder lesion types where I'd expect our model to be weaker, and we don't surface a 'low confidence, do not rely on this' state.

### ASSISTANT
What specific exclusion criteria or confidence thresholds are you planning to implement to mitigate the risk of providing unreliable classifications for difficult lesions, and how will you ensure these are documented and aligned with the EU AI Act’s transparency requirements? [P3.D10]

### USER
Right now the GP just sees one of three labels — benign, suspicious, or urgent. We have the Platt-calibrated class probabilities internally but don't surface them or a saliency map / Grad-CAM, so there's no visible explanation of why the model picked that class.

### ASSISTANT
What specific transparency mechanisms are you planning to implement to provide meaningful explanations of the model’s decisions, such as displaying class probabilities or visual explanations like Grad-CAM, in line with the EU AI Act’s transparency obligations for high-risk systems? [P3.D10]

### USER
Plan: log every prediction + GP's final decision; quarterly performance review.

### ASSISTANT
What specific steps are you taking to ensure that the logged predictions and GP decisions are securely stored, accessible for audits, and used to continuously improve the model’s performance in compliance with the EU AI Act’s accountability and transparency requirements? [P3.D10]

### USER
Our plan is to log every prediction plus the GP's final decision and review performance quarterly; that gives us traceability, though I accept quarterly is slow and we don't yet have live drift or anomaly monitoring.

### ASSISTANT
What specific real-time monitoring mechanisms are you planning to implement to detect model drift or anomalies in predictions, and how will these align with the EU AI Act’s requirement for continuous oversight and risk management? [P3.D10]

### USER
EfficientNet-B4 fine-tuned on ISIC 2020. Calibrated with Platt scaling.

### ASSISTANT
What specific validation strategies are you using to ensure that the EfficientNet-B4 model, fine-tuned on ISIC 2020 data, is robust to distributional shifts in real-world clinical settings, and how does this align with the EU AI Act’s requirements for data quality and model reliability? [P3.D8]

### USER
Our EfficientNet-B4 was fine-tuned and tested on dermatoscopic ISIC images, but in the product the GP takes an ordinary smartphone photo at the practice, so the real-world capture conditions (lighting, focus, no dermatoscope) differ from our validation data and we haven't quantified the accuracy drop from that yet.

### ASSISTANT
What specific steps are you taking to quantify and mitigate the performance degradation of the EfficientNet-B4 model when deployed in real-world clinical settings with variable lighting, focus, and non-dermatoscopic imaging, and how will this align with the EU AI Act’s requirements for data quality and model reliability? [P3.D8]

### USER
We fine-tuned on ISIC 2020, which is skewed toward Fitzpatrick I-III light skin. I'll be honest that we expect weaker performance on darker skin tones and we haven't measured or corrected for that bias yet — Fitzpatrick type is only an optional field for us.

### ASSISTANT
What specific steps are you planning to take to measure and mitigate the performance disparity of the EfficientNet-B4 model across Fitzpatrick skin types, and how will this align with the EU AI Act’s requirements for fairness, non-discrimination, and transparency in high-risk AI systems? [P3.D9]

### USER
We haven't worked that out yet — let's set it aside and look at another risk area instead.

### USER
Thanks for the conversation. Could you produce a brief structured risk report now? Use HERA dimension IDs (e.g. [P1.D2]) and group risks by severity. End the report with a list of dimensions you didn't get to cover.

### ASSISTANT
**HERA Risk & Safety Risk Report for DermaScan**  
*EU + CH, mHealth app with AI classification of skin lesions*

---

### **High Severity Risks (Critical for Compliance & Safety)**

**[P1.D2]** *Data Security & Anonymization*  
- **Risk**: Pseudonymized data is stored for 5 years, but GDPR erasure-on-request workflow is not fully implemented, especially for data in retraining sets.  
- **Mitigation**: Implement GDPR-compliant erasure workflows, including mechanisms to remove data from retraining sets. Reference: **GDPR Art. 17** (Right to Erasure).

**[P2.D3]** *Data Governance & Anonymization*  
- **Risk**: Pseudonymization may not meet GDPR’s "adequate security" standard, increasing re-identification risk.  
- **Mitigation**: Use stronger anonymization techniques where possible, and document pseudonymization methods. Reference: **GDPR Art. 4(11)**.

**[P3.D10]** *Transparency & Explainability*  
- **Risk**: No visible explanation of model decisions (e.g., class probabilities, Grad-CAM).  
- **Mitigation**: Implement transparency mechanisms such as class probability displays or visual explanations. Reference: **EU AI Act Art. 38** (Transparency).

**[P3.D8]** *Model Robustness & Data Quality*  
- **Risk**: Model is trained on dermatoscopic ISIC images, but deployed on ordinary smartphone photos with variable lighting and focus.  
- **Mitigation**: Quantify performance degradation in real-world settings and validate with diverse data. Reference: **EU AI Act Art. 35** (Robustness).

**[P3.D9]** *Fairness & Non-Discrimination*  
- **Risk**: Model is biased toward Fitzpatrick I-III skin types; performance on darker skin tones is unmeasured.  
- **Mitigation**: Conduct fairness audits and adjust model training to include diverse skin types. Reference: **EU AI Act Art. 34** (Fairness).

---

### **Medium Severity Risks (Important for Compliance & Safety)**

**[P1.D1]** *Data Protection by Design*  
- **Risk**: No formal documentation of GDPR erasure workflow, especially for retraining data.  
- **Mitigation**: Document and implement GDPR-compliant erasure procedures. Reference: **GDPR Art. 25**.

**[P3.D10]** *Accountability & Traceability*  
- **Risk**: Logging of predictions and GP decisions is planned but not yet implemented.  
- **Mitigation**: Implement secure logging and audit trails. Reference: **EU AI Act Art. 39** (Accountability).

**[P3.D8]** *Model Validation & Continuous Monitoring*  
- **Risk**: No live drift or anomaly monitoring; quarterly reviews are slow.  
- **Mitigation**: Implement real-time monitoring for model drift and performance anomalies. Reference: **EU AI Act Art. 35**.

---

### **Low Severity Risks (Minor but Worth Monitoring)**

**[P2.D1]** *Data Source & Training*  
- **Risk**: Model trained on ISIC 2020, which is skewed toward Fitzpatrick I-III.  
- **Mitigation**: Use diverse training data and validate across skin types. Reference: **EU AI Act Art. 34**.

---

### **Dimensions Not Covered in This Report**

- **[P1.D4]** *Data Subject Rights & Consent*  
- **[P1.D5]** *Data Portability*  
- **[P4.D1]** *Human Oversight & Control*  
- **[P4.D2]** *User Autonomy & Control*  
- **[P5.D1]** *Safety & Clinical Validation*  
- **[P5.D2]** *Clinical Evidence & Evaluation*  
- **[P6.D1]** *System Integration & Interoperability*  
- **[P7.D1]** *Sustainability & Environmental Impact*  

---

Let me know if you’d like to dive deeper into any of these areas.

Now produce the JSON judgement object.